ARTICLE | Clinical News
Tresiba insulin degludec regulatory update
February 2, 2015 8:00 AM UTC
EMA’s CHMP recommended approval of an expanded label for Novo Nordisk’s Tresiba insulin degludec to treat Type I and Type II diabetes to include its use in patients ages 1-17. Novo Nordisk markets the...